Tango Therapeutics (TNGX) announced the retirement of its Chief Executive Officer, Dr. Barbara Weber, effective January 8, 2026. Dr. Weber, the company’s founding CEO, will become Executive Chair for 2026 and then serve as non-executive chair starting in 2027. She is succeeded by Dr. Malte Peters. In her new capacity as Executive Chair, Weber will remain closely involved with the senior management team of Tango, supporting the company’s strategic priorities and working with Dr. Peters to ensure a seamless transition and continued clinical execution throughout 2026. Alexis Borisy, the current Board Chair, will transition to Lead Independent Director.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX:
- Tango Therapeutics appoints Sung Lee to board of directors
- Tango Therapeutics Adds Independent Director to Strengthen Governance
- Strategic Positioning and Synergy Potential Drive Buy Rating for Tango Therapeutics’ Vopimetostat
- Tango Therapeutics initiated with a Buy at Stifel
- Tango Therapeutics Enters New Sales Agreement with Leerink